(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 February 2013 (21.02.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/024097 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/EP2012/065906

(22) International Filing Date:
14 August 2012 (14.08.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

11177658.9	16 August 2011 (16.08.2011)	EP
61/523,861	16 August 2011 (16.08.2011)	US
61/647,539	16 May 2012 (16.05.2012)	US
61/654,097	1 June 2012 (01.06.2012)	US

(71) Applicant *(for all designated States except US)*: **MORPHOSYS AG** [DE/DE]; Lena-Christ-Strasse 48, 82152 Martinsried/Planegg (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AMERSDORFER, Jutta** [DE/DE]; Lena-Christ-Str. 48, 82152 Martinsried / Planegg (DE). **STEIDL, Stefan** [DE/DE]; Ebenböckstr. 25, 81241 München (DE). **WINDERLICH, Mark** [DE/DE]; Implerstr. 52, 81371 München (DE). **KROHN, Susanne** [DE/DE]; Haidelweg 22a, 81241 München (DE). **ROJKJAER, Lisa** [CA/CH]; Frohmoosstrasse 38h, CH-8908 Hedingen (CH).

(74) Agent: **HUTTER, Bernd**; Lena-Christ-Str. 48, 82152 Planegg-Martinsried (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,


[Continued on next page]

WO 2013/024097 A1

(54) Title: COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A NITROGEN MUSTARD

Figure 5

Normalized specific killing; SD; MEC-1 target cells pretreated with Bendamustine (Ben) for 48 h before ADCC; pool of 3 independent experiments with 3 different effector cell donors



The figure shows the averages from the data shown in Table 2.

(57) Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*